drugset / Trial / NCT03466268
Study to Evaluate the Safety and Anti-tumor Activity of SCC244
NaSingle-groupOpen-labelTreatment
Summary
This study evaluates the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of SCC244 in patients with advanced solid tumors with c-Met Alterations.
Timeline
- Start
- 2017-09-14
- Primary completion
- 2023-01-09
- Completion
- 2023-01-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gumarontinib | Small molecule | 100 mg | — |
| Subject | Gumarontinib | Small molecule | 200 mg | — |
| Subject | Gumarontinib | Small molecule | 300 mg | — |
| Subject | Gumarontinib | Small molecule | 400 mg | — |